Sulthiame add-on treatment in children with epileptic encephalopathy with status epilepticus: an efficacy analysis in etiologic subgroups

Basit Öğe Kaydı
dc.contributor.authorKanmaz, Seda
dc.contributor.authorSimsek, Erdem
dc.contributor.authorSerin, Hepsen Mine
dc.contributor.authorYilmaz, Sanem
dc.contributor.authorAktan, Gul
dc.contributor.authorTekgul, Hasan
dc.contributor.authorGokben, Sarenur
dc.date.accessioned2020-12-01T11:59:18Z
dc.date.available2020-12-01T11:59:18Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractPurpose Sulthiame (STM) has been recommended as an effective antiepileptic drug (AED) in children with epileptic encephalopathy with status epilepticus in sleep (ESES). the aim of this study is to evaluate the efficacy of STM add-on treatment in children with pattern of ESES with respect to the etiologic subgroup. Methods Twenty-nine children with ESES pattern with three different etiologic subgroups (epileptic syndromes: 14, structural/infectious: 9, unknown: 6) who were given STM as add-on treatment were included into the study. the efficacy of STM was evaluated in terms of seizure control, electroencephalography (EEG) findings, need of the new AEDs after add-on STM, and behavioral and cognitive improvement. Results the range of the follow-up duration after add-on STM treatment was between 5 and 51 months. At the end of 1 year of STM treatment, the most successful electrophysiologic improvement was identified in the well-defined epileptic syndrome group; epileptic syndrome, 71.4% (10/14); structural/infectious, 33.3% (3/9); and unknown, 0% (0/6). Patients who had complete response or persistent ESES pattern at the 3rd month were still in the same condition at the 6th and 12th months. However, the ESES pattern reappeared in 35.2% of the patients who had partial electrophysiological improvement at the 3rd month. in the epilepsy syndrome group, eight out of ten patients who had either complete or partial EEG response after 1 year of STM treatment displayed behavioral and cognitive improvement. Conclusion Sulthiame might be a valid add-on treatment of ESES especially in children with epilepsy syndromes.en_US
dc.identifier.doi10.1007/s10072-020-04526-yen_US
dc.identifier.issn1590-1874
dc.identifier.issn1590-3478
dc.identifier.pmid32592101en_US
dc.identifier.scopus2-s2.0-85087286462en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1007/s10072-020-04526-y
dc.identifier.urihttps://hdl.handle.net/11454/62226
dc.identifier.wosWOS:000543622500002en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer-Verlag Italia Srlen_US
dc.relation.ispartofNeurological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSulthiameen_US
dc.subjectESESen_US
dc.subjectEpilepsy syndromesen_US
dc.titleSulthiame add-on treatment in children with epileptic encephalopathy with status epilepticus: an efficacy analysis in etiologic subgroupsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu